STK10 regulates platelet function in arterial thrombosis and thromboinflammation.
Summary
This mechanistic study shows that STK10 is a key kinase in platelets, directly phosphorylating ILK (Ser343) to regulate multiple activation endpoints. Platelet STK10 deletion dampened thromboinflammation and improved survival in murine sepsis, with STK10/ILK activation also elevated in septic patients.
Key Findings
- STK10 is expressed in human/mouse platelets; its deletion impairs hemostasis and arterial thrombosis.
- STK10 directly phosphorylates ILK at Ser343; ILK phosphorylation decreases with STK10 deletion.
- Deletion of platelet STK10 reduces aggregation, alpha-granule release, αIIbβ3 activation, procoagulant activity, spreading, and clot retraction.
- STK10 deletion attenuates platelet–neutrophil interactions and NETs, ameliorates thromboinflammation, and improves survival in murine sepsis; STK10/ILK activation increases in sepsis patients.
Clinical Implications
Suggests STK10-ILK signaling as a target to modulate platelet-driven thromboinflammation in sepsis and cardiovascular disease; motivates development of selective STK10 inhibitors or pathway modulators.
Why It Matters
Identifies a previously unrecognized platelet kinase pathway linking to sepsis survival and thromboinflammation, offering a tractable therapeutic target. Integrates phosphoproteomics, protein interaction, enzymology, in vivo models, and patient data.
Limitations
- Preclinical study without pharmacologic STK10 inhibition data or clinical intervention
- Potential off-target or compensatory pathways not fully delineated
Future Directions
Develop selective STK10 inhibitors; evaluate safety/efficacy in thromboinflammatory models; biomarker studies to stratify patients by platelet STK10/ILK activation.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic/translational evidence; not a clinical trial
- Study Design
- OTHER